Killen J Y, Mitchell E P, Hoth D F, Willis L L, Gullo J J, Smith F P, Schein P S, Woolley P V
Cancer. 1982 Oct 1;50(7):1258-61. doi: 10.1002/1097-0142(19821001)50:7<1258::aid-cncr2820500706>3.0.co;2-1.
We have tested methyl glyoxal bis-guanyl hydrazone (NSC 32946) for antitumor activity in patients with colorectal carcinoma and non-small cell bronchogenic carcinoma. The drug dose was 500 mg/m2 administered by single weekly injection, and with a provision dose escalation. No responses were seen in 38 evaluable patients with colorectal cancer, including 17 who had received no prior chemotherapy. Three responses were seen among 42 patients with bronchogenic carcinoma. These included one each with epidermoid carcinoma, adenocarcinoma and large cell anaplastic carcinoma. None of these responders had received prior chemotherapy. Toxicity of the drug was predominantly gastrointestinal, namely nausea, vomiting and diarrhea, and tended to increase with repeated drug doses. Neurologic symptoms of various sorts were also prominent. We conclude that methyl-G is of marginal benefit in this dose and schedule to patients with bronchogenic carcinoma.
我们已经对丙酮醛双胍腙（NSC 32946）在结直肠癌和非小细胞支气管癌患者中的抗肿瘤活性进行了测试。药物剂量为500mg/m²，每周单次注射，并可逐步增加剂量。38例可评估的结直肠癌患者中未见反应，其中17例此前未接受过化疗。42例支气管癌患者中有3例出现反应。这些反应包括1例表皮样癌、1例腺癌和1例大细胞间变性癌。这些有反应的患者均未接受过先前的化疗。该药物的毒性主要为胃肠道反应，即恶心、呕吐和腹泻，且随着药物剂量的重复使用有加重趋势。各种神经症状也很突出。我们得出结论，在此剂量和给药方案下，丙酮醛双胍腙对支气管癌患者的益处有限。
